{"id":54253,"date":"2023-02-27T11:04:27","date_gmt":"2023-02-27T10:04:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/"},"modified":"2023-02-27T11:04:27","modified_gmt":"2023-02-27T10:04:27","slug":"cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/","title":{"rendered":"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>PhysioMimix HT System increases productivity, cost-effectiveness and data robustness<\/i>\n<\/li>\n<li>\n<i>Developed to enable earlier adoption of predictive human liver Organ-on-a-Chip models in drug discovery workflows<\/i>\n<\/li>\n<li>\n<i>New PhysioMimix multi-chip consumable plate containing 48 liver chips also launched<\/i>\n<\/li>\n<\/ul>\n<p>CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the commercial launch of the PhysioMimix\u2122 Single-organ Higher Throughput (HT) System. The Company\u2019s first HT system has been designed to overcome adoption barriers currently limiting the use of predictive human liver models within drug discovery workflows, to enable use within earlier stages where larger-scale comparative studies that investigate the efficacy, disposition or safety of lead candidate drugs are required.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/5\/cn-bio-logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg\"><\/a><\/p>\n<p>\nThe PhysioMimix HT System provides users with a scalable solution, combining a significantly reduced cost-per-chip with increased run capacity. Launching alongside the system is a new multi-chip consumable plate, the Liver-48 plate, which faithfully miniaturizes CN Bio\u2019s well-characterized and validated human liver model for applications that include predicting drug-induced liver injury or determining drug metabolism\/hepatic clearance<sup>1<\/sup>, and the modelling of various prevalent liver diseases such as Non-alcoholic steatohepatitis (NASH)<sup>2<\/sup>.\n<\/p>\n<p>\nAllowing 48 liver chip assays within one laboratory-standard SBS footprint, the plate supports the incorporation of replicates, controls and seven-point dose-response curves to improve data robustness and reproducibility. Multiple Liver-48 plates can be run simultaneously to provide a total capacity of 144 chips per HT System, with potential to expand this further in response to consumer demand. Together, the new technology enables the benefits of human-relevant OOC insights to be realized earlier in drug discovery, facilitating more confident decision making and the potential recovery of overlooked therapeutic candidates.\n<\/p>\n<p>\nIn support of New Approach Methodologies (NAMs) such as MPS, the FDA Modernization Act 2.0 has recently passed to remove the mandatory requirement for animal testing of developmental drugs for toxicity where enhanced performance is proven using <i>in vitro<\/i> alternatives<sup>3<\/sup>. The potential of MPS technology is further reinforced by the FDA\u2019s decision to expand its collaborative research following several successful projects with CN Bio, most recently to investigate the company\u2019s Gut\/Liver model for human drug bioavailability studies<sup>4<\/sup>.\n<\/p>\n<p>\n<b>Dr Paul Brooks, CEO, CN Bio, said: <\/b>\u201c<i>The timing of this launch is particularly pertinent following significant US legislative changes, which should alleviate another barrier to more widespread OOC adoption and emphasises the potential of MPS to revolutionise drug discovery processes. Representing the next generation of OOC technology, the PhysioMimix Single-organ HT System extends and complements our existing portfolio, enabling scientists to pick the solution, or solutions, that best meet their research needs and phase of drug discovery,<\/i><i> <\/i><i>to bring more confident decision making to the process and the potential recovery of flawed drugs.\u201d<\/i>\n<\/p>\n<p>\nCN Bio\u2019s PhysioMimix OOC range of MPS is designed to reliably bridge the gap between existing preclinical methods and human studies. Complementing the simplicity of traditional <i>in vitro<\/i> cell culture and the complexity of <i>in vivo<\/i> animal models, the Company&#8217;s suite of hardware, consumables and assay protocols, delivers accurate predictions where traditional approaches fall short. The MPS enables users to culture primary human cells as 3D microtissues in a fully perfused microenvironment that incorporates key elements of the human immune system. Faithfully recreating the physiology and function of human tissues and organs in an <i>in vitro<\/i> environment, they offer a path forward for the testing of new human-specific therapeutic modalities and the insights from MPS to be realized earlier and at more stages of drug discovery than achieved to-date.\n<\/p>\n<p>\nFor more information on CN Bio\u2019s PhysioMimix OOC range of products, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcn-bio.com%2Fphysiomimix-ooc%2F&amp;esheet=53348213&amp;newsitemid=20230227005393&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcn-bio.com%2Fphysiomimix-ooc%2F&amp;index=1&amp;md5=f2cdfdd3779b5dd1a7acc32dddcae045\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/cn-bio.com\/physiomimix-ooc\/<\/a>\n<\/p>\n<ol class=\"bwlistdecimal\">\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fascpt.onlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fcts.12969&amp;esheet=53348213&amp;newsitemid=20230227005393&amp;lan=en-US&amp;anchor=Characterizing+the+Reproducibility+in+using+a+Liver+Microphysiological+System-for+Assaying+Drug+Toxicity%2C+Metabolism+and+Accumulation&amp;index=2&amp;md5=e561a71cf358ac1ec40651c0a3f57ea9\" rel=\"nofollow noopener\" shape=\"rect\">Characterizing the Reproducibility in using a Liver Microphysiological System-for Assaying Drug Toxicity, Metabolism and Accumulation<\/a>. Rubiano <i>et al.,<\/i> 2020\n<\/li>\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34526653%2F&amp;esheet=53348213&amp;newsitemid=20230227005393&amp;lan=en-US&amp;anchor=Modelling+human+liver+fibrosis+in+the+context+of+non-alcoholic+steatohepatitis+using+a+microphysiological+system&amp;index=3&amp;md5=e00b08122936970a3c0e79f0755d0483\" rel=\"nofollow noopener\" shape=\"rect\">Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system<\/a> Kostrzewski <i>et al<\/i>., 2021\n<\/li>\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2022%2F12%2F23%2F2579295%2F0%2Fen%2FCongress-Approves-Landmark-Measure-to-Reduce-Animal-Testing.html%23%3A~%3Atext%3DWASHINGTON%252C%2520D.C.%252C%2520Dec.%252023%252C%25202022%2520%2528GLOBE%2520NEWSWIRE%2529%2520--%2Cdogs%252C%2520primates%252C%2520and%2520other%2520animals%2520in%2520laboratory%2520tests.&amp;esheet=53348213&amp;newsitemid=20230227005393&amp;lan=en-US&amp;anchor=Congress+Approves+Landmark+Measure+to+Reduce+Animal+%28globenewswire.com%29&amp;index=4&amp;md5=90d93db55765fff2ec2c4dda46f4abb9\" rel=\"nofollow noopener\" shape=\"rect\">Congress Approves Landmark Measure to Reduce Animal (globenewswire.com)<\/a>\n<\/li>\n<li>\nPress release (17<sup>th<\/sup> January 2023): <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcn-bio.com%2Fthe-fda-further-expands-collaboration-with-cn-bio-to-evaluate-the-physiomimix-multi-organ-microphysiological-system%2F&amp;esheet=53348213&amp;newsitemid=20230227005393&amp;lan=en-US&amp;anchor=The+FDA+further+expands+collaboration+with+CN+Bio+to+evaluate+the+PhysioMimix+Multi-organ+microphysiological+system&amp;index=5&amp;md5=3e01f93295e18a2beec093e8f2996a48\" rel=\"nofollow noopener\" shape=\"rect\">The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system<\/a>\n<\/li>\n<\/ol>\n<p class=\"bwalignc\">\n<b>ENDS<\/b>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nLily Jeffery<br \/>\n<br \/>Tel: +44(0)7891477378<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#108;i&#x6c;&#121;&#46;&#x6a;&#101;f&#x66;&#101;r&#x79;&#64;z&#x79;&#109;e&#x63;&#111;m&#x6d;&#117;n&#x69;&#99;a&#x74;&#105;o&#x6e;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x6c;&#105;l&#x79;&#46;j&#x65;&#102;f&#x65;&#114;y&#x40;&#122;y&#x6d;&#101;c&#x6f;&#109;m&#x75;&#110;i&#x63;&#97;t&#x69;&#111;n&#x73;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PhysioMimix HT System increases productivity, cost-effectiveness and data robustness Developed to enable earlier adoption of predictive human liver Organ-on-a-Chip models in drug discovery workflows New PhysioMimix multi-chip consumable plate containing 48 liver chips also launched CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54253","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PhysioMimix HT System increases productivity, cost-effectiveness and data robustness Developed to enable earlier adoption of predictive human liver Organ-on-a-Chip models in drug discovery workflows New PhysioMimix multi-chip consumable plate containing 48 liver chips also launched CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-27T10:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System\",\"datePublished\":\"2023-02-27T10:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/\"},\"wordCount\":680,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005393\\\/en\\\/1723373\\\/21\\\/cn-bio-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/\",\"name\":\"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005393\\\/en\\\/1723373\\\/21\\\/cn-bio-logo.jpg\",\"datePublished\":\"2023-02-27T10:04:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005393\\\/en\\\/1723373\\\/21\\\/cn-bio-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005393\\\/en\\\/1723373\\\/21\\\/cn-bio-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/","og_locale":"en_US","og_type":"article","og_title":"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System - Pharma Trend","og_description":"PhysioMimix HT System increases productivity, cost-effectiveness and data robustness Developed to enable earlier adoption of predictive human liver Organ-on-a-Chip models in drug discovery workflows New PhysioMimix multi-chip consumable plate containing 48 liver chips also launched CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-27T10:04:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System","datePublished":"2023-02-27T10:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/"},"wordCount":680,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/","url":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/","name":"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg","datePublished":"2023-02-27T10:04:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230227005393\/en\/1723373\/21\/cn-bio-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54253"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54253\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}